En savoir plus
Justinius Kerner, a German medical officer and poet, was the first to realize that botulinum toxin potentially might be useful for therapeutic purposes. Kerner made this observation in 1822, but he did not call the toxin "botulinum toxin. " Instead, Kerner called it the substance in "wirkenden stoffes," which translates to "bad sausages. " Kerner realized that there was a "fat poison" or "fatty acid" within sausages that produced the toxic effects that we now know as botulism. Nearly a century would pass before the bacterium producing the toxin would be isolated and the toxin ultimately renamed "botulinum toxin. " As farsighted as Kerner was, it is doubtful that even he could have predicted just how much potential therapeutic punch was packed within his wirkenden stoffes. It was not until 1978, more than a century and a half after Kerner's prediction, that Dr. Allan Scott received Food and Drug Administration approval to test botulinum toxin type A in human volunteers. We do not yet have a comprehensive understanding of precisely how botulinum toxin works in the human body or how our bodies fully respond to the toxin. We do know that it temporarily paralyzes muscle by inhibiting the release of acetylcholine, and it also appears to inhibit the release of other neurotransmitters.
Table des matières
History and Mechanism of Action.- Spasticity.- Radiation Fibrosis Syndrome.- Low Back Pain.- Piriformis Syndrome.- Plantar Fasciitis.- Headache.- Spasmodic Dysphonia.- Sialorrhea and Frey's Syndrome.- Cosmetic Applications.- Hyperhydrosis.- Urological Applications.- Gastrointestinal Applications.- Blepharospasm.- Economics, Immunity, and Future Directions.
Résumé
This volume outlines and examines current understanding of botulinum toxin and its various therapeutic applications. The editors explore how this novel compound fits into a wide variety of treatment algorithms across medical subspecialties. Each chapter focuses on a particular symptom and explains how botulinum toxin is currently used for treatment. The chapter authors are all leaders in their fields and are respected for their progressive approach to treatment. Coverage also examines questions of immunity and explores economic issues, and attempts to forecast future directions for this novel and somewhat mysterious drug. This book encourages responsible research into new and novel uses of botulinum toxin.
Texte suppl.
From the reviews:
"This book presents many of the clinical uses of the relatively new drug, botulinum toxin. … the book attempts to cover nearly all uses of the medication known to the assorted authors, including potential treatments for which there is little peer-reviewed literature. The purpose is to provide an overview of this medication, and present clinical scenarios in which the drug might be an appropriate choice. … The target audience should be clinicians (physicians and therapists) ... ." (Ross Bogey, Doody’s Review Service, January, 2008)
Commentaire
From the reviews:
"This book presents many of the clinical uses of the relatively new drug, botulinum toxin. ... the book attempts to cover nearly all uses of the medication known to the assorted authors, including potential treatments for which there is little peer-reviewed literature. The purpose is to provide an overview of this medication, and present clinical scenarios in which the drug might be an appropriate choice. ... The target audience should be clinicians (physicians and therapists) ... ." (Ross Bogey, Doody's Review Service, January, 2008)
